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Abstract
In this study, the characterization of insulin (auto)antibodies has been described, mainly in terms of concentration (q),
affinity (Ka) and Ig (sub)isotypes by Surface Plasmon Resonance (SPR) in two particular clinical cases of individuals with
severe episodes of impaired glycemia. Subject 1 suffers from brittle diabetes associated with circulating insulin antibodies
(IA) due to insulin treatment. Subject 2 has insulin autoantibodies (IAA) associated with hypoglycemia in spite of not being
diabetic and not having ever received exogenous insulin therapy. After conventional screening for IA/IAA by radioligand
binding assay (RBA), we further characterized IA/IAA in sera of both patients in terms of concentration (q), affinity (Ka) and Ig
(sub)isotypes by means of SPR technology. In both cases, q values were higher and Ka values were lower than those
obtained in type 1 diabetic patients, suggesting that IA/IAA:insulin immunocomplexes could be responsible for the
uncontrolled glycemia. Moreover, subject 1 had a predominat IgG1 response and subject 2 had an IgG3 response. In
conclusion, SPR technology is useful for the complete characterization of IA/IAA which can be used in special cases where
the simple positive/negative determination is not enough to achieve a detailed description of the disease fisiopathology.
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Introduction
Circulating Insulin antibodies (IA) are often detected in diabetic
patients undergoing insulin treatment, however, these antibodies
rarely interfere with the therapy and/or are associated with
hypoglycemic or hyperglycemic episodes. However, a subset of
insulin-treated patients with extremely high levels of IA are insulin
resistant, with mean insulin binding capacities greater than
216 nM (30,000 microunits of insulin/ml serum) [1]. Ishizuka
et al. [2] have described two cases of patients who produced low
affinity and high insulin binding capacity of these antibodies while
undergoing insulin treatment. These patients suffered from severe
daytime hyperglycemia and early morning hypoglycemia which
could be the result of massive volumes of insulin binding to the IA
inducing hyperglycemia and later on, hypoglycemia due to the
release of insulin from the immunocomplexes, [3]. Thus, brittle
diabetes is the term used to describe uncontrolled type 1 diabetes
which has been reported to occur in about 1 to 2% of patients who
experience dramatic variation in blood glucose levels during the
daytime. The glucose levels imbalance, in turn, leads to frequent
episodes of keto-acidosis requiring that the patient be hospitalised
[4,5].
On the other hand, there are some cases where the episodes of
hypoglycemia are a consequence of the presence of high levels of
insulin autoantibodies (IAA) to endogenous insulin, despite never
having received insulin injections. The Insulin Autoimmune
Syndrome (IAS) is a well known example of the latter clinical
status. This syndrome, first reported by Hirata et al. [6], has a
strong association with HLA DR4 [7,8] and with drug-induced
autoimmunization caused by the administration of drugs contain-
ing sulphydryl groups (i.e. methimazol, thiamazol, glutathione or
D-penicillamine) [9].
IA are routinely assessed by the Radioligand Binding Assay
(RBA) first described by Kurtz and Nabarro [10], whereas IAA
were first detected by an optimized RBA using mono (A14) [125I]-
insulin as tracer [11]. When RBA signals exhibit high levels (e.g.:
B%.20%) it is feasible to obtain the absolute parameters of the
antibody:antigen interaction, by displacement Radioimmunoassay
(RIA), using the conventional tracer or [35S]-Cysteine proinsulin
[12]. Such parameters are the affinity constant (the median K0, for
polyclonal antibodies, [13]) and the specific antibody concentra-
tion (q), usually expressed as binding capacity (BC). In this regard,
Achenbach et al. [14] have carried out a workshop to assess
whether four laboratories could reproducibly measure IAA affinity
in coded sera from non-diabetic relatives of patients with type 1
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diabetes, newly diagnosed patients, and healthy blood donors, and
whether combining affinity with autoantibody titre could improve
concordance and performance of IAA assays. This was evaluated
by competitive binding using constant amounts of [125I]-insulin
and increasing quantities of unlabeled human insulin.
The Surface Plasmon Resonance (SPR) technology is an
alternative method to RIA to determine the primary interaction
parameters. Moreover, these parameters can be measured in a
real-time fashion. The biosensors based on SPR technology detect
changes in the refraction index produced when an analyte (in this
case antibodies) binds to its counterpart (in this case antigens) fixed
on a sensor chip surface. This interaction can be expressed in
terms of the kinetic association constant (k1) and kinetic
dissociation constant (k-1), and also in terms of equilibrium affinity
constant (Ka), where Ka= k1/k-1.
In addition, by means of SPR it is possible to determine the Ig
(sub)isotypes involved in the humoral immune response. The
maturation of the immune response against insulin in preclinical
type 1 diabetes has been assessed in sera samples from the Finnish
Type 1 Diabetes Prediction and Prevention Study (DIPP), by
observing the emergence of various isotypes of IAA in children
with HLA-DQB1-conferred disease susceptibility. Results demon-
strated that those children who progressed to type 1 diabetes had a
dominant IgG1, whereas IgG3 antibodies were more prevalent
before the initiation of exogenous insulin therapy [15,16].
The aim of the present study was to characterize IA/IAA in
terms of concentration (q), affinity (Ka) and Ig (sub)isotypes by
SPR technology in two representative high titer IA/IAA sera from
patients who presented brittle diabetes (Subject 1) or hypoglycemia
episodes (Subject 2 with presumptive IAS) associated with such
(auto)antibodies.
Materials and Methods
Case Report
Subject 1 is a 12-year-old Caucasian infant diagnosed with type
1 diabetes at 18 months of age. The patient had been administered
exogenous insulin thenceforward, developing lipodystrophy in the
places of injection. He presented brittle diabetes with a glycemia
range of 55–400 mg/dl. At 4 years of age, the patient’s body mass
index (BMI) was 16.5. The IA binding rate measured by RBA was
B%=48.2% (cut off value = 3.28%). Treatment was initiated with
NPH human insulin but further changed to porcine insulin
injected around the lypodystrophic sites, which improved lypoa-
trophy. Since glycemia was still uncontrolled, treatment varied
over time from GlarginaTM (17 U/day) to LevemirTM (21 U/day).
Despite the changes in the therapeutic schedule, the episodes of
fasting hypoglycemia recurred and hypoglycemic bouts started to
occur after meals. After 10 years of evolution, the patient
continued with regular metabolic control, lipodystrophy,
BMI= 19 and HbA1c of 8.6%.
Subject 2 is at present a 27-year-old Caucasian woman who had
never received insulin treatment nor thiol-related drugs. Since she
was 10 years old she has presented hypoglycemic symptoms. At 11
years old her BMI was 15.3 and her current BMI is 21.9. IAA
measured by RBA revealed high binding signals to insulin
(B%=62.1%, cut off value = 3.28%). All other type 1 diabetes
humoral markers assayed (glutamic acid decarboxylase autoanti-
bodies –GADA–, protein tyrosine phosphatase IA-2 autoantibod-
ies –IA-2A– and zinc transporter 8 autoantibodies –ZnT8A–) were
negative. Furthermore, DQB1 genotyping did not demonstrate the
presence of alleles associated with type 1 diabetes susceptibility.
The initial treatment was 40 mg/day of methilprednisolone but
gradually it was reduced to 2 mg/day since she had presented
persistent episodes of hyperglycemia. When hypoglycemia reap-
peared, former doses of the corticoid were used. Eighteen months
later, her treatment was switched to 50 mg of Acarbose previous
meal time, together with the prescription of a diet without
carbohydrates of rapid absorption. As the episodes of hypoglyce-
mia and hyperglycemia continued to occur, she was subjected to
plasmapheresis and treatment with the monoclonal antibody
RituximabTM without obtaining any improvement of her clinical
condition. Since then, the time course of IAA levels has been
systematically evaluated, showing no significant decrease despite
the therapy used. Other potential endocrine abnormalities that
could cause hypo- and hyperglycemia were ruled out.
Control Group
Sera from 28 children and adolescents admitted to the Nutrition
Service at the J. P. Garrahan Pediatric Hospital (Buenos Aires,
Argentina), with a mean age of 8.3164.20 at diagnosis were
collected before or within 72 h of insulin treatment initiation.
Figure 1. Representative sensorgrams obtained by SPR technology. A: Schematic representation of how antigen:antibody interaction
parameters were calculated. B: Schematic representation of an Enhancement Assay to determine (sub)isotypes of specific Ig.
doi:10.1371/journal.pone.0084099.g001
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Type 1 diabetes was diagnosed according to WHO criteria [16].
The starting group included 71 children and adolescents attending
the service from June 1994 to July 1996. As the hospital is a
referral centre, patients came from all over Argentina and were
mainly Caucasians. All these patients were tested in parallel for
humoral markers of diabetes, IAA/proinsulin autoantibodies
(PAA), GADA, IA-2A and ZnT8A. Most patients (71.8%) were
GADA–positive. The second marker in frequency was ZnT8A
(69.0%) followed by IA-2A (66.2%) and IAA/PAA (36.6%) (Table
S1).
Blood samples were collected after overnight fasting and sera
were stored at 20uC until assayed. The collection of serum samples
from newly diagnosed type 1 diabetic patients, and the respective
protocols were approved by the Ethical Committees of the J. P.
Garrahan National Pediatric Hospital.
Written consent from all participants involved in this study as
well as parental consent when being a minor was obtained.
Radioligand Binding Assay (RBA)
(Auto)antibodies were first assessed by routinely screening using
RBA [12] and fulfilling the criteria mentioned by Davidson and
DeBra [1] based on BC of (auto)antibodies.
Briefly, cDNA coding for human proinsulin (PI) was transcribed
and translated using a rabbit reticulocyte lysate system in the
presence of [35S]cysteine (New England Nuclear, Boston, MA),
according to the manufacturer’s instructions. After overnight
refolding, favoured by a disulphide reduction-reoxidation proce-
dure, [35S]-PI was isolated by reverse-phase HPLC. Sera (30 ml)
were incubated for seven days at 4uC with 1,000 cpm of [35S]-PI
in 90 ml of RBA buffer (50 mM sodium phosphate, 100 mM
NaCl, pH 7, 0.1% Aprotinin and 0.1% bovine serum albumin). In
order to isolate the immunocomplexes, 50 ml of a 50% suspension
of Protein G-Sepharose 4B FF (Amersham Biosciences, Piscat-
away, NJ) in RBA buffer were subsequently added. Samples were
centrifuged and supernatants were discarded. Pellets were washed
four times with 200 ml of RBA buffer, suspended in 100 ml 1%
SDS, and centrifuged (5 min at 6,0006g). Supernatants were
carefully transferred to appropriate vials for scintillation counting,
which was performed for 5 min each vial. Results were calculated
as B%=1006bound cpm/total cpm and expressed as
SDscore= (B%–BC%)/SDC, where BC% was the mean B% of
control sera and SDC its standard deviation. Thirty normal control
sera were included. BC% was normally distributed. An assay was
considered positive if SDscore.3.
Table 1. Comparative IA/IAA data achieved with sera from subjects 1 and 2.
Subject 1 Subject 2 Type 1 Diabetes
A RBA Signal (B%) 48.2 61.2 11.6969.02a
Precision unit (SDs) 26.72 46.75 12.4861.748a
B RIA/Scatchard BC (U/L) 76 195 ND
C SPR k1 (610
5 M21s21) 36.8 5.70 ND
k-1 (s
21) 0.36 0.17 ND
q (61029 M) 250.55 352.25 85.5269.980a
Ka (610
6 M21) 10.30 3.37 105.40631.70a
A: Conventional data: B% and SD score (SDs) obtained from RBA signals; B: Binding Capacity (BC) determined by RIA and Scatchard processing; C: SPR derived
parameters: kinetic constants (k1 and k-1), concentration (q) and affinity (Ka) calculated by the BIAevaluation software (BIAcore
TM).
aMean values calculated from 28 IAA positive type 1 diabetic patients.
ND: Not Determined.
doi:10.1371/journal.pone.0084099.t001
Figure 2. Fitting of experimental data (full line) to theoretical binding curves (dotted lines) in the affinity measurements of specific
(auto)antibodies. A: IA affinity measurements of subject 1. B: IAA/PAA affinity measurements in subject 2.
doi:10.1371/journal.pone.0084099.g002
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Radioimmunoassay (RIA) and Binding Capacity (BC)
When B% values of IA/IAA were higher than 20%, RIAs
together with conventional data processing were carried out in
order to determine absolute values of IA/IAA in terms of
concentration expressed as BC: insulin units per litre of serum
(U ins/L serum) [17]. Values of BC.30 U ins/L serum were
considered demonstrative of the involvement of hyperglycemic
and hypoglycemic episodes [1].
Surface Plasmon Resonance Analysis (SPR)
The assessment of antibody:antigen interaction parameters, q
and Ka, was performed as previously described [18]. All serum
samples were centrifuged before injecting into the biosensor.
IA/IAA concentration. To evaluate q of IA/IAA, the
experiments were carried out over a carboxymethylated-dextran
CM5 sensor chip (GE Healthcare, Uppsala, Sweden) surface
immobilized with standard proinsulin (Eli Lilly, Indianapolis, IN,
USA) in an amount corresponding to 1600 Resonance Units (RU).
The binding rates were measured after 120 s in running buffer
(0.14 M NaCl, 2.7 mM KCl, 1.5 mM KPO4H2, 8.1 mM
Na2PO4H, pH 7.4, 0.05% Tween 20). After each antigen-
antibody interaction, a regeneration step was carried out using
10 mM glycine-HCl, pH 1.5. All sensorgrams were corrected by
subtracting the signal from the reference flow cell.
A standard curve (RU vs antibody concentration) was prepared
by using a rabbit anti-human-proinsulin polyclonal serum
(300 nM determined by RIA). The concentrations used were:
75 nM, 37.50 nM, 18.75 nM, 9.38 nM, 6.69 nM, 2.34 nM,
1.17 nM and 0.59 nM. When measuring the binding rates, sera
from both patients were diluted 1/10 and 1/30 in running buffer.
For each sample the concentration of specific (auto)antibodies was
derived from the standard curve. All experiments were carried out
at 25uC with a flow rate of 10 ml/min.
IA/IAA affinity. For the determination of IA/IAA affinity,
the sensor chip was prepared by using lower concentrations of
immobilized antigen (300 RU). Assays were carried out at 20uC
using a flow rate of 10 ml/min. A 1:1 binding model was used.
Each patient’s serum was used diluted 1/2, 1/4 and 1/8 in
running buffer. In either case these starting samples were diluted
1/2 with carboxymethyl-dextran and NaCl to a final concentra-
tion of 1 mg/ml and 0.35 M, respectively, in order to eliminate
nonspecific reactions. Each sample was injected over 300 s and the
binding rate in running buffer was measured after 300 s. The
association rate constant (k1), the dissociation rate constant (k21),
and the equilibrium constant (Ka), were calculated from the
sensorgrams analysis using the Biacore T100 Evaluation Software
version 2.0 (BiacoreH T100 Software Handbook) (Fig. 1A).
IA/IAA (Sub)isotyping. To perform the (sub)isotyping of Ig
involved in the specific humoral immune response, each serum
was analysed diluted 1/10 in running buffer, and injected during
300 s, over a sensor chip surface with proinsulin immobilized in an
amount corresponding to 2000 RU. Anti-human isotype antibod-
ies -anti-IgG, anti-IgM and anti-IgA- (DAKO Denmark S/A,
Glostrup, Denmark) and anti-human IgG subisotype antibodies -
anti-IgG1, anti-IgG2, anti-IgG3, anti-IgG4 (BD Biosciences
Pharmingen, San Diego, CA, USA) were subsequently injected
diluted 1/50 in running buffer over 120 s, previous the
regeneration step. All sensorgrams were corrected by subtracting
the signal from the reference flow cell. Net response in RU was
informed as the difference between enhancement level and basal
enhancement level (Fig. 1B).
Results
In this work, we have analysed two particular clinical cases of
patients with high IA/IAA titre together with severe uncontrolled
glycemia. As described previously, subject 1 was a boy with brittle
diabetes and lipodystrophy in insulin injection sites associated to
the presence of IA. Subject 2 had recurrent hypoglycemic episodes
related to the presence of IAA, but he had never had neither signs
nor clinic history of type 1 diabetes.
Figure 3. Isotyping of IA/IAA in subjects 1 and 2 by SPR
technology. A: Sensorgrams generated by the injection of anti-human
IgG. The ellipse emphasizes a positive response. B: Sensorgrams
generated by the injection of anti-human IgM. C: Sensorgrams
generated by the injection of anti-human IgA. The arrow indicates
where in the sensorgram the anti-isotype antibodies were injected.
doi:10.1371/journal.pone.0084099.g003
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(Auto)antibody titers were first determined by conventional
RBA and expressed as B% and SD score. In addition, RIA with
Scatchard analysis was performed (Table 1).
IA/IAA Concentration and Affinity
By means of SPR technology it was possible to determine q and
Ka of the specific (auto)antibodies. The q value of IA present in
subject 1 serum was 250.5561029 M, while q value of IAA in
subject 2 serum was 352.2561029 M. Both values were signifi-
cantly high when compared to those of sera from type 1 diabetic
patients. Regarding Ka values, these were 10.3610
6 M21 and
3.376106 M21 for subject 1 and 2, respectively, and were
significantly lower than those found in type 1 diabetic patients.
Figure 2 shows fits of the experimental curves to theoretical
binding curves generated by BIA-evaluation software.
The results concerning concentration and affinity of both
subjects studied compared to type 1 diabetic patients are
summarized in Table 1.
IA/IAA Isotyping and Subisotyping
As expected for a mature secondary response, IA/IAA were
IgG (961 RU and 2534 RU for subject 1 and 2, respectively),
whereas the other isotypes were undetectable (Fig. 3). When
analysing the IgG subisotypes involved in the humoral immune
response, subject 1 had a predominant IgG1 response (83 RU),
while subject 2 had an IgG3 response (875 RU) (Fig. 4).
Discussion
It is known that a subset of insulin-treated patients with
extremely high levels of insulin antibodies are insulin resistant,
with mean insulin Binding Capacities greater than 216 nM
(30,000 microunits of insulin/ml serum) [1]. For such patients,
the species of insulin used for therapy is usually changed (e.g.
human insulin to analogue insulin or vice versa and occasionally to
sulphated insulin). Besides, a very rare syndrome has been
described, in which patients develop extremely high levels of
insulin autoantibodies after exposure to sulfhydryl containing
medications (e.g. methimizole, penicillamine) [9]. This clinical
entity has been termed Insulin Autoimmune Syndrome or Hirata’s
syndrome [19]. These patients usually present hypoglycemia
which disappears after discontinuation of the medication. In
addition to this MHC-restricted syndrome (almost all with
DRB1*0406), some patients have monoclonal insulin autoanti-
bodies produced by B lymphocyte tumors.
In the present work, two particular clinical entities have been
analysed whose pathologies are associated to the presence of high
Figure 4. Subisotyping of IgG IA/IAA in subjects 1 and 2 by SPR technology. A: Sensorgrams generated by the injection of anti-human IgG1.
B: Sensorgrams generated by the injection of anti-human IgG2. C: Sensorgrams generated by the injection of anti-human IgG3. D: Sensorgrams
generated by the injection of anti-human IgG4. The ellipses in A and B emphasize a positive response. The arrow indicates where in the sensorgram
the anti-subisotype antibodies were injected.
doi:10.1371/journal.pone.0084099.g004
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levels of insulin (auto)antibodies together with transient episodes of
hypoglycemia. It is important to emphasize that subject 1 has type
1 diabetes with irregular control of glycemia despite receiving
insulin therapy and that subject 2 is non-diabetic. Thus, it was of
extreme interest to evaluate not only IA/IAA titres but also its
primary interaction parameters (q and Ka). This latter was done in
order to achieve a better description of both pathologies and
consequently to be able to understand the causes of the impaired
glycemias.
IA/IAA titers determined by RBA, and expressed in terms of
B% and SDs, were extremely high in both cases (Table1). When
these values were dissected in terms of their two components (q
and Ka) by means of SPR, it was demonstrated that q values were
relatively higher and Ka values were lower than those obtained for
type 1 diabetic patients [18]. These results support the hypothesis
that the IA/IAA:insulin immunocomplexes could be responsible
for the uncontrolled glycemia. The alternating states of intra and
interprandial hyperglycemia could be caused by a high amount of
these circulating (auto)antibodies sequestering the insulin, and thus
inhibiting its activity on the target tissues. In the particular case of
subject 2, this level of IAA would be forcing pancreatic beta cells to
produce and secrete more insulin. However, and because IAA are
of low affinity and IAA:insulin immunocomplexes are of low
molecular weight, there is a circulating pool of insulin bound to
autoantibodies which lead to spontaneous release of high
quantities of the hormone in addition to the insulin that is being
released from pancreatic beta cells. All these events lead to
frequent and severe symptoms of interprandial hypoglycemias.
On the other hand, subject 1 had severe signs of lipodystrophy
in the insulin injection sites, problably related to the local deposit
of immunocomplexes. A strong association between lipoatrophy
and lipohypertrophy with insulin antibodies in children and
adolescents with type 1 diabetes has been reported [20]. The
authors have suggested that autoimmune phenomena with insulin
play a role in the development of both abnormalities of the adipose
tissue. Another study has demonstrated that patients with severe
lipodystrophy are sternly insulin resistant, which can be attributed
to defects in insulin action in both liver and muscle [21].
The latter signs in subject 1 had disappeared when treatment
was changed to porcine insulin. Nevertheless, the alternate
episodes of hyper and hypoglycemia went on along with the
permanence of high levels of IA.
Despite the apparent similarity in the high levels of specific Igs,
when the subisotypes of IgG involved in the humoral response
were analysed, it was also demonstrated by SPR, that both patients
exhibited different profiles. As expected, in subject 1,, the IA
isotype was IgG1 accordingly to a typical type 1 diabetes [15],
while in subject 2, the IAA isotype was IgG3 suggesting a benign
monoclonal gammopathy [22,23] associated to a pathogenic T-
helper 1 response. It is well known that the isotype profile of
antigen-specific autoantibodies reflects the T-helper 1/T-helper 2
(Th1/Th2) balance of the immune response, which can change
during the prediabetic period. Islet cell autoimmunity may start as
a non-pathogenic Th2 response to pancreatic beta-cell that
gradually shifts to a pathogenic Th1 response, reflecting the
maturation of the humoral immune response in individuals who
progress to type 1 diabetes [24,25]. Accordingly, the IA/IAA
isotype analysis in these two patients evidenced that the
autoimmune response is a complex process with different
pathways that lead to the elicitation of humoral responses that
lead to dissimilar physiopathological conditions.
Isotypes of insulin autoantibodies have been evaluated in the
BabyDiab study and in studies from Finland [26,27] with the
observation that a broader response to insulin and strong IgG1
responses is associated with a somewhat greater risk of progression
to diabetes. In this regard, Hoppu et al. have reported the
prevalence of various isotypes of IAA in genetically susceptible
young children identified from the general population. There was
some heterogeneity in the IAA isotype response, but most
frequently an IgG1-IAA response was the first to appear, whereas
IgG4-IAA appeared later on. In addition, they have demonstrated
that the initial IAA response was characterized by a dominant
peak comprising IgG1-IAA followed by an IgG3-IAA response in
progressors, whereas IgG3 dominance was not seen initially among
the non-progressors [27]. These data show that genetically
susceptible young children who progress to clinical type 1 diabetes
are characterized by strong IgG1 and IgG3 responses to insulin,
indicating a powerful insulin-specific Th1 response.
In all these reported cases, IgG subclass and isotype-specific
antibodies were measured by means of a modified conventional
radioimmunoassay where the protein A Sepharose precipitation
was replaced by monoclonal subclass-specific antibodies linked to
streptavidin agarose. It is noteworthy that only the antibodies
detected with the radioassay formats are associated with type 1
diabetes [28] and that the detection with plate-binding asays is
problematic [28]. Due to the latter phenomena, we have chosen
SPR technology to characterize the isotypes of IA/IAA in these
two clinical cases.
To sum up, it can be concluded that conventional IA/IAA
assessment by RBA in these sort of patients presents serious
practical limitations because it is a cuasi- quantitative assay by
means of which it is only possible to determine titre as bound
percentage (B%). Thus, complementary RIA/Scatchard analysis
and separate isotyping tests were required to obtain a complete
characterization of the humoral specific response. In this respect, it
is important to highlight that with RIA/Scatchard analysis, only
the concentration of specific (auto)antibodies is determined, but
there is no information about the affinity.
In this sense, the present work introduces a new approach based
on SPR technology for further analysis of the (auto)antibodies
involved in the development of the disease. The methodology
described herein, could be recommended in longitudinal studies of
diabetic patients with high humoral autoimmune response and in
patients where the simple positive or negative determination are
not conclusive in the diagnosis of the disease.
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